Stifel Reiterates Buy Rating on Krystal Biotech (KRYS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St futures ease as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges down against euro
Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté
August 28, 2024 7:00 AM EDTDécolleté indication selected for Phase 2 study expected to start next year
Conference call to discuss results scheduled for Wednesday, August 28, 2024 at 4:30 p.m. ET
PITTSBURGH, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (Jeune), a wholly owned subsidiary of Krystal Biotech, Inc. (Krystal) (NASDAQ: KRYS) leveraging Krystals clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced... More
